Blood test may spare breast cancer patients from chemo
NCT ID NCT06970912
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This study tests whether a blood test (ctDNA) can identify women with early-stage, hormone-positive breast cancer who can safely avoid chemotherapy. Instead of chemo, they receive a targeted pill (dalpiciclib) plus hormone therapy before surgery. The goal is to reduce side effects while keeping cancer from coming back. About 393 women will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smartwatch could spot nerve damage before it starts
- Exercise during chemo: a new weapon to preserve strength?
- Virtual therapy may ease breast cancer treatment side effects
- A gentle jog might be the key to better sleep for breast cancer survivors
- Six-Gene clue: could a simple test forecast lung spread in breast cancer?
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?